CytoMed Therapeutics Ltd
About CytoMed Therapeutics Ltd
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $15.3M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.3M
- Shares outstanding
- 13.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 14, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CytoMed Therapeutics Ltd.
Write a review
News about CytoMed Therapeutics Ltd
News & sentiment via Polygon.io
